760,595 Shares in Edwards Lifesciences Corporation $EW Bought by Corient Private Wealth LP

Corient Private Wealth LP bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 760,595 shares of the medical research company’s stock, valued at approximately $24,071,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. TrinityBridge Ltd acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $27,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the 4th quarter worth about $26,000. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $25,000. Kemnay Advisory Services Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $27,000. Finally, JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at about $25,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,501 shares of company stock worth $408,213 over the last quarter. 0.31% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

EW has been the subject of several recent analyst reports. UBS Group started coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Evercore restated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. BTIG Research upped their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, Truist Financial increased their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Stock Up 0.3%

Shares of Edwards Lifesciences stock opened at $90.19 on Friday. The stock has a market capitalization of $51.93 billion, a P/E ratio of 51.83, a PEG ratio of 2.36 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $89.54 and a two-hundred day moving average price of $85.03. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.